Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

23.31 +0.86 (+3.83%)
Streaming Delayed Price Updated: 1:41 PM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 620,702
Open 22.55
Bid (Size) 23.28 (200)
Ask (Size) 23.32 (200)
Prev. Close 22.45
Today's Range 22.55 - 23.72
52wk Range 18.29 - 42.37
Shares Outstanding 70,814,462
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Pharma (NASDAQ:RARE) Dips After Q1 Miss as Pipeline Catalysts Loom ↗
Via Chartmill

Performance

YTD
-1.2%
-1.2%
1 Month
-7.0%
-7.0%
3 Month
+15.5%
+15.5%
6 Month
-29.0%
-29.0%
1 Year
-35.6%
-35.6%

More News

Read More
News headline image
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ:RARE) Investors of the April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Ultragenyx 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
RARE Deadline: Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
ULTRAGENYX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action – RARE
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
RARE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
From SkyMedia, LLC
Via GlobeNewswire
News headline image
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ: RARE) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by April 6, 2026
From Berger Montague
Via GlobeNewswire
News headline image
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE
From Pomerantz LLP
Via GlobeNewswire
News headline image
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
From SkyMedia, LLC
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ: RARE) Investors of the Upcoming April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
RARE Investor Alert: Ultragenyx Pharmaceutical Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit
From Robbins LLP
Via Business Wire
News headline image
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
From Kahn Swick & Foti, LLC
Via GlobeNewswire

Frequently Asked Questions

Is Ultragenyx Pharmaceutical Inc. - Common Stock publicly traded?
Yes, Ultragenyx Pharmaceutical Inc. - Common Stock is publicly traded.
What exchange does Ultragenyx Pharmaceutical Inc. - Common Stock trade on?
Ultragenyx Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock?
The ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock is RARE on the Nasdaq Stock Market
What is the current price of Ultragenyx Pharmaceutical Inc. - Common Stock?
The current price of Ultragenyx Pharmaceutical Inc. - Common Stock is 23.31
When was Ultragenyx Pharmaceutical Inc. - Common Stock last traded?
The last trade of Ultragenyx Pharmaceutical Inc. - Common Stock was at 05/20/26 01:41 PM ET
What is the market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock?
The market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock is 1.65B
How many shares of Ultragenyx Pharmaceutical Inc. - Common Stock are outstanding?
Ultragenyx Pharmaceutical Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.